Immunotherapy combo not approved for advanced kidney cancer patients on the NHS
People with a certain type of advanced kidney cancer will not be able to have a combination of two immunotherapy drugs on the NHS in England.
Dec 14, 2018
2
11
People with a certain type of advanced kidney cancer will not be able to have a combination of two immunotherapy drugs on the NHS in England.
Dec 14, 2018
2
11
A long-term follow up of people on an international clinical trial has confirmed the benefit of immunotherapy for certain patients with advanced (stage 3 or 4) melanoma.
Feb 25, 2015
0
72
Patients with advanced melanoma whose cancer does not respond to treatment with widely used immunotherapy drugs known as PD-1 inhibitors are often switched to treatment with a second type of immunotherapy drug—a CTLA-4 ...
Apr 8, 2022
0
8
A combination of two immunotherapy drugs, ipilimumab and nivolumab, has stopped or reversed the progression of advanced melanoma for five years or more in one in two patients, according to a study led by The Royal Marsden ...
Sep 28, 2019
0
9
The combination of first-line nivolumab and ipilimumab demonstrated an improvement of overall survival for patients with unresectable malignant pleural mesothelioma compared to platinum-based chemotherapy, according to research ...
Aug 8, 2020
0
2
A combination of immunotherapy drugs will be made available to NHS patients with advanced and aggressive kidney cancer on the NHS in England.
Apr 5, 2019
0
1
A combination immunotherapy treatment of nivolumab plus ipilimumab was associated with no improvement in survival for advanced cancers other than melanoma, when compared to nivolumab alone, according to a recent Northwestern ...
Sep 22, 2023
0
59
One in two patients with metastatic melanoma is alive with combination immunotherapy, according to late breaking results of the CheckMate 067 trial presented at the ESMO Congress 2019 in Barcelona, Spain.
Sep 28, 2019
0
10
Results from the S1609 DART clinical trial, which tested an immunotherapy combination of ipilimumab plus nivolumab in 53 cohorts of patients with rare cancers, are being reported for five cohorts of patients who had rare ...
Apr 17, 2023
0
15
Ipilimumab is an immunotherapy that has revolutionized the treatment of malignant melanoma, a very aggressive type of skin cancer, according to Theurich. About 20 percent of patients who receive ipilimumab achieve durable ...
Jul 27, 2016
0
7
Ipilimumab (also known as MDX-010 or MDX-101), marketed as Yervoy, is a drug used for the treatment of melanoma, a type of skin cancer. It is a U.S. Food and Drug Administration (FDA) approved human monoclonal antibody developed by Bristol-Myers Squibb, and works by activating the immune system.
Additionally, ipilimumab is undergoing clinical trials for the treatment of non-small cell lung carcinoma (NSCLC), small cell lung cancer (SCLC) and metastatic hormone-refractory prostate cancer.
This text uses material from Wikipedia, licensed under CC BY-SA